First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

PURPOSE. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Díaz-Rubio, Eduardo, Gómez-España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Abad, Albert, Valladares, Manuel, Rivera, Fernando, Safont, Maria J., Martínez de Prado, Purificación, Gallén, Manuel, González, Encarnación, Marcuello, Eugenio, Benavides, Manuel, Fernández-Martos, Carlos, Losa, Ferrán, Escudero, Pilar, Arrivi, Antonio, Cervantes, Andrés, Dueñas, Rosario, López-Ladrón, Amelia, Lacasta, Adelaida, Llanos, Marta, Tabernero, Jose M., Antón, Antonio, Aranda, Enrique
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Academia-Pharma Intersect
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267817/
https://ncbi.nlm.nih.gov/pubmed/22234633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0249
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky